The stock of Tenax Therapeutics, Inc. (NASDAQ: TENX) closed the previous session at $2.08, meaning its value has risen 307.76% higher than its 52-week low. In intraday trading, Tenax stock hit a low of $2.03 and a high of $2.47.
A recent trading session has witnessed an intraday change of just 16.85% while TENX stock has had a 52-week high of $3.68 and a low of $0.51. An increase in TENX stock accompanied the positive results of a phase 2 study on its candidate for the treatment of cardiovascular disease.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
The TENX study found what?
A specialty pharmaceutical company, Tenax Therapeutics, focuses on identifying and developing products with high unmet medical needs for cardiovascular diseases and pulmonary diseases. TENX facilitates access to world-class scientific advisory teams, which include globally recognized experts in pulmonary hypertension.
Read More
On Friday, Tenax announced that it had published positive results from its Phase 2 HELP study that examined levosimendan’s efficacy in patients with Cardiopulmonary Hypertension associated with Heart Failure.
- TENX has published a new publication titled Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Placebo-Controlled HELP Trial.
- This article was published in the Journal of the American College of Cardiology.
- Through this 6-week study, TENX examined the haemodynamics of individuals who were invasively monitored by their cardiovascular system as well as secondary clinical outcomes such as a 6-minute walk test.
- According to the TENX study published in the journal, 84% of the participants responded.
- The primary endpoint of exercise-PCWP was not significantly reduced by levosimendan, compared with placebo, but PCWP was effectively reduced across all phases of exercise.
- Compared to a control group, 6 MWD experienced a 29.5 meter improvement from the levosimendan treatment.
TENX’s further plans:
Levosimendan is currently in Phase 2 clinical trials to treat PH-HFpEF and developed by Tenax (TENX), which also has the rights to develop and commercialize this drug. Based on the TENX study’s results, further study of levosimendan in PH-HFpEF patients is warranted since this is the first drug that could demonstrate improved cardiomyopathy and improved six-minute walking distance compared to placebo.